Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to evaluate the sensitivity of the fecal protein dual-index test reagent for the detection of colorectal cancer (CRC).
The project uses fecal hemoglobin and transferrin dual-index combined with reagents that can be self-tested at home (referred to as fecal protein dual-index detection reagents), combined with colorectal cancer risk factor questionnaires, to carry out colorectal cancer screening in people of specific ages in the city, aiming to achieve early screening, early diagnosis and early treatment, and evaluate the effect of fecal protein dual-index detection reagents in early screening of colorectal cancer, so as to provide a scientific basis for optimizing the national screening program.
Age
45 - 74 years
Sex
ALL
Healthy Volunteers
Yes
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
Start Date
September 1, 2024
Primary Completion Date
January 15, 2025
Completion Date
January 15, 2025
Last Updated
January 21, 2025
25,000
ACTUAL participants
Lead Sponsor
The First Affiliated Hospital of Xinxiang Medical College
Collaborators
NCT04704661
NCT06696768
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions